PERSONIFICATION OF CARDIORESPIRATORY REHABILITATION IN MYOCARDIAL INFARCTION ON COVID 19

Abstract

The complicated course of COVID-19 with the occurrence of myocardial infarction requires a personalized approach to medical and non-medical treatment of patients in acute, subacute and long-term stages of rehabilitation. Restoration of impaired functions should begin in the acute period of the disease. Patients with myocardial infarction on the background of COVID-19 should be guided by a program of bed and extended bed rest under the control of electrocardiogram using therapeutic exercises №1 and №2 and emphasis on diaphragmatic breathing without the use of patient positioning and postural drainage. In the subacute period of myocardial infarction on the background of a negative PCR test in some patients may remain shortness of breath. At this stage of rehabilitation static and dynamic breathing exercises, psychotherapy, hardware physiotherapy are used. In case of myocardial infarction, a semi-bed and free regime should be used with the use of therapeutic exercises №3 and №4 with the use of breathing exercises. and to improve the ventilatory function of the lungs by increasing the mobility of the chest, excursions of the diaphragm, strengthening the respiratory muscles. We believe that traditional breathing techniques, which are aimed at inflating the alveoli, should not be used in patients without additional examinations. Patients with myocardial infarction on the background of COVID-19 disease are more severe, more frequent arrhythmic complications and progression of heart failure. The developed rehabilitation program and personalized approach to treatment made it possible to significantly reduce the incidence of these complications. Rehabilitation activities with the participation of a multidisciplinary team with a physician and physiotherapist, physical therapist, psychologist, infectious disease specialist, pulmonologist, cardiologist, psychologist, nutritionist increases the effectiveness of normalization of the patient, prevents the development of pulmonary fibrosis, improves the quality of life of patients after COVID-19 against the background of concomitant cardiovascular pathology, reduces the frequency of various complications.